NRG GY018

Primary Category:

Treatment Protocols

Disease Category:

Endometrial, Gynecologic

Status:

Open

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVB or Recurrent Endometrial Cancer

Eligible for screening study DCP 001

GY018 is no longer open to registration of dMMR patient population, effective August 15, 2022. Accrual of pMMR patients will continue.

This protocol has additional regulatory requirements to be completed prior to registering any patients at your site.  Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.

NCT#03914612